AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22429362
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion at 1.0‐4.0 μg/kg per h
Trial: 30079635
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion
Trial: 22429362
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion >2.0 μg/kg per h during the preanhepatic phase
Trial: 22429362
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (generally accepted inotropic and vasopressor agents)
Trial: 18757528
Drug: Psychotropic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medication
Trial: 16311183
Drug: Sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual (SL) liquid buprenorphine
Trial: 16311183
Drug: Sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual (SL) tablet buprenorphine
Trial: 12425406
Drug: Fluid augmentation
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid augmentation during the first 36 hours after surgery
Trial: 8678366
Drug: Cancer that
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer that has spread through the capsule
Trial: 1892146
Drug: Ofloxacin, 400
RxNorm normalized name: Ofloxacin, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin, 400 mg every 12 hours, administered orally or by nasogastric tube
Trial: 1892146
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (individual investigator's best selection of therapy administered parenterally)
Trial: 6660930
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intracervical prostaglandin E2 (PGE2) gel
Trial: 6660930
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by i.v. oxytocin
Trial: 6660930
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intracervical prostaglandin E2 (PGE2) gel followed by another dose of PGE2-gel and subsequent i.v. oxytocin
Trial: 27993166
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention (twice-weekly voice messages about diabetes prevention and control)
Trial: 27993166
Drug: Participatory community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participatory community group intervention (monthly group meetings for men and women to address diabetes issues)
Trial: 22188557
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (2.5 g)
Trial: 22188557
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (5.0 g)
Trial: 22188557
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (2.5 g) with t-shirt
Trial: 22188557
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (any dose) with washing
Trial: 22188557
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (upper arms/shoulders application site)
Trial: 22188557
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (any dose)
Trial: 7614530
Drug: NIF CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF CC 30 mg daily
Trial: 7614530
Drug: NIF GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF GITS 30 mg daily
Trial: 7758054
Drug: NIF GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF GITS 60 mg daily
Trial: 7758054
Drug: NIF CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF CC 60 mg daily
Trial: 23686821
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) 40mg administered subcutaneously three times weekly (tiw) for 12 months
Trial: 10789885
Drug: Amitriptyline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (100 mg)
Trial: 9323616
Drug: RV3 rotavirus
RxNorm normalized name: ROTAVIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV3 rotavirus vaccine (1 mL oral dose, 6.5 x 10(5) FFU/mL)
Trial: 7870966
Drug: Alprazolam (APZ)
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam (APZ) 0.003 mg/kg
Trial: 7870966
Drug: Alprazolam (APZ)
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam (APZ) 0.007 mg/kg
Trial: 7870966
Drug: Alprazolam (APZ)
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam (APZ) 0.02 mg/kg
Trial: 29949873
Drug: Synbiotics (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (2.5 g once daily for 12 weeks)
Trial: 27926473
Drug: 75g oral
RxNorm normalized name: Mesalamine 0.375g Oral capsule, biphasic release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75g oral glucose load (OGTT)
Trial: 22545251
Drug: Implant-supported crowns
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implant-supported crowns
Trial: 18234565
Drug: Non-adrenergic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adrenergic treatment (control group)
Trial: 10368449
Drug: Anthracycline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline treatment (cumulative doses between 45 and 1150 mg/m2, median 270 mg/m2)
Trial: 2050093
Drug: Wholemeal bread
RxNorm normalized name: Wholemeal bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wholemeal bread (50 g available carbohydrate)
Trial: 23656707
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread (50 g available carbohydrate)
Trial: 2050093
Drug: Grained wholemeal
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grained wholemeal rye bread (50 g available carbohydrate)
Trial: 2050093
Drug: Grained wholemeal
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grained wholemeal rye bread with 40% dried figs (50 g available carbohydrate)
Trial: 7862884
Drug: Fluvoxamine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (150 mg daily)
Trial: 25205320
Drug: Probiotic consortium
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic consortium (Lab4) plus 50 mg vitamin C
Trial: 24791343
Drug: Metronidazole 1%
RxNorm normalized name: METRONIDAZOLE 1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 1% gel
Trial: 11759644
Drug: Intravenous fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous fluconazole for six weeks
Trial: 3422682
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (two chemotherapeutic regimens)
Trial: 3422682
Drug: Chemotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy after recurrence
Trial: 27306255
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (100 μg)
Trial: 28368941
Drug: Continuous ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ropivacaine wound infusion (0.2%)
Trial: 23418863
Drug: Lifestyle Wellness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle Wellness Program (LWP) - 12-week group intervention, one-hour weekly sessions discussing dietary choices, lifestyle, physical activity, and self-esteem.
Trial: 21198573
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg frovatriptan
Trial: 16565362
Drug: High-dose retinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose retinol (50,000 IU oral retinol for 30 days)
Trial: 2629642
Drug: Education programme
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education programme consisting of two packages of education with four weekly meetings
Trial: 25655226
Drug: XR-NTX (injections)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX (injections)
Trial: 22219100
Drug: Total cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total cholesterol treatment goal (< 4.5 mmol/L)
Trial: 22219100
Drug: Triglycerides treatment
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglycerides treatment goal (< 1.7 mmol/L)
Trial: 22219100
Drug: LDL cholesterol
RxNorm normalized name: LDL cholesterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL cholesterol treatment goal (< 2.6 mmol/L)
Trial: 22219100
Drug: HDL cholesterol
RxNorm normalized name: HDL cholesterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDL cholesterol treatment goal (> 1.0 mmol/L in men and > 1.3 mmol/L in women)
Trial: 22219100
Drug: Meeting three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meeting three treatment goals (HbA1c, BP and cholesterol)
Trial: 22219100
Drug: Meeting two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meeting two out of three treatment goals
Trial: 22219100
Drug: Meeting only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meeting only one out of three treatment goals
Trial: 19805643
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at bedtime
Trial: 19805643
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at awakening
Trial: 15542159
Drug: dl-alpha tocopheryl
RxNorm normalized name: DL-alpha tocopheryl acetate
DrugBank: DL-alpha tocopheryl acetate (DB14477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-alpha tocopheryl acetate 500 mg twice a day orally plus pentoxifylline 400 mg twice a day orally
Trial: 7969965
Drug: Selegiline 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 40 mg
Trial: 3583073
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine at 1800 h
Trial: 3583073
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine at 2200 h
Trial: 24245491
Drug: Integrated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated intervention (cognitive behavioral therapy) for alcohol, anxiety, and/or depression
Trial: 16611342
Drug: Early CsA‐ME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early CsA‐ME (8 mg/kg/day starting on day 0)
Trial: 16611342
Drug: Delayed CsA‐ME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed CsA‐ME (8 mg/kg/day starting on day 6)
Trial: 10755246
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg bd for 7 days)
Trial: 10755246
Drug: Trimethoprim‐sulphamethoxazole (TMPSMX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim‐sulphamethoxazole (TMPSMX; 160‐800 mg bd) or alternative therapy
Trial: 8610430
Drug: High-dose fluconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluconazole (400 mg/day)
Trial: 22776066
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy intervention (3 months intervention from an occupational therapist)
Trial: 15670980
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus high dose multiple antioxidants (ascorbic acid 6100 mg/day, dl-alpha-tocopherol 1050 mg/day, beta-carotene 60 mg/day)
Trial: 25481791
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (paclitaxel and carboplatin)
Trial: 27716152
Drug: Low-dose carvedilol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carvedilol (maximum dose: 12.5 mg/day)
Trial: 27716152
Drug: Low-dose carvedilol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carvedilol
Trial: 17009838
Drug: Fluid group
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid group (Bronchicum Elixir S, 6 x 5 ml daily)
Trial: 17009838
Drug: Drops group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drops group (Bronchcium Tropfen, 5 x 1 ml daily)
Trial: 14759070
Drug: T4 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T4 (100 microg daily)
Trial: 14759070
Drug: T3 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T3 (25 microg daily)
Trial: 11072156
Drug: C-RT (cisplatinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-RT (cisplatinum 40 mg/m(2)/weekly + radiation therapy)
Trial: 11072156
Drug: RT (radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT (radiation therapy alone)
Trial: 1385010
Drug: Continuous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-dose aprotinin (7 x 10(6) KIU)
Trial: 1385010
Drug: Continuous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-dose aprotinin
Trial: 1385010
Drug: Continuous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-dose aprotinin and Single bolus of aprotinin
Trial: 27480757
Drug: 1 × 10(10) colony-forming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 10(10) colony-forming units of Lactobacillus rhamnosus GG, twice daily
Trial: 23431028
Drug: Ambulatory oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory oxygen (AO) 2 L/min from a portable oxygen concentrator
Trial: 18251212
Drug: Fixed-combination tablet
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination tablet of an ACE inhibitor (perindopril) with a diuretic (indapamide) (4 mg/l,250 mg)
Trial: 9010691
Drug: LIPO-PGE1 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPO-PGE1 (50 micrograms bolus injection)
Trial: 9010691
Drug: PGE1-cyclodextrin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1-cyclodextrin (60 micrograms infusion over 2 hours)
Trial: 1739236
Drug: Acetazolamide, 250
RxNorm normalized name: AcetaZOLAMIDE, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide, 250 mg orally
Trial: 6377891
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg with meals three times daily)
Trial: 26611571
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and saffron
Trial: 26611571
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and placebo
Trial: 20013046
Drug: Treatment responder
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment responder status
Trial: 16472588
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg/20 mg
Trial: 16472588
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg/40 mg
Trial: 16472588
Drug: Adalimumab 160
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 160 mg/80 mg
Trial: 9604449
Drug: UVB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB plus 100 g of calcipotriol (50 micrograms/g) ointment per week
Trial: 9604449
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment alone (100 g/week)
Trial: 9604449
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (UVB plus calcipotriol)
Trial: 2422467
Drug: tiapamil 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiapamil 1 mg/kg body weight
Trial: 2422467
Drug: placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (20 ml 0.9% NaCl)
Trial: 31575503
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 and carboplatin (AUC 2 μg×h/mL) on days 1 and 8 (group 1)
Trial: 31575503
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and carboplatin plus intravenous trilaciclib 240 mg/m2 on days 1 and 8 (group 2)
Trial: 28464321
Drug: DS-3801b 50
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-3801b 50 mg
Trial: 23556466
Drug: Early-invitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-invitation group (food supplements starting at ∼9 weeks gestation, 2.5 MJ d(‐1), 6 days a week)
Trial: 23556466
Drug: Usual-invitation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-invitation group (food supplements starting at ∼20 weeks gestation)
Trial: 17309935
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D supplementation (500 mg calcium carbonate with 200 IU vitamin D twice daily)
Trial: 12184523
Drug: Synthetic motilin
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic motilin infusion
Trial: 15985559
Drug: Anti-H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H pylori treatment
Trial: 9536937
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day for one month followed by 20 mg/day for six months
Trial: 7634631
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for 7 days postoperatively
Trial: 7634631
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no non-steroidal antiinflammatory drug)
Trial: 869151
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0‐125% or 0‐25% bupivacaine solutions
Trial: 25941160
Drug: Linagliptin with
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin with insulin (mild renal impairment)
Trial: 25941160
Drug: Linagliptin with
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin with insulin (moderate renal impairment)
Trial: 25941160
Drug: Linagliptin with
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin with insulin (severe renal impairment)
Trial: 22470030
Drug: Antioxidant therapy
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy (β‐carotene, vitamin C, vitamin E)
Trial: 11341475
Drug: Tolterodine 2mg
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolterodine 2mg twice daily
Trial: 11341475
Drug: Oxybutynin 5mg
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5mg 3 times daily
Trial: 11341475
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily extended-release tolterodine capsules
Trial: 9022531
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil concentrate (FOC) 5 g
Trial: 9022531
Drug: Purified eicosapentaenoic
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified eicosapentaenoic acid (EPA) 3 g
Trial: 9022531
Drug: Placebo (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (olive oil ethyl esters) 5 g
Trial: 7889665
Drug: Ro 24-0238,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 24-0238, 10% solution in diethylene glycol monoethyl ether
Trial: 3065929
Drug: Intramuscular ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone (CFT) 100 mg/kg once daily
Trial: 3065929
Drug: Combined intramuscular
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intramuscular ampicillin (160 mg/kg/day) and chloramphenicol (100 mg/kg/day) given every 6 h (AMC)
Trial: 3065929
Drug: Intramuscular ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ceftriaxone (CFT)